RNAi-based nanomedicines for targeted personalized therapy

Ala Daka; Dan Peer

doi:https://doi.org/10.1016/j.addr.2012.08.014

RNAi-based nanomedicines for targeted personalized therapy

Ala Daka, Dan Peer

Department of Cell Research and Immunology

Tel Aviv University

Research output: Contribution to journal › Review article › peer-review

Abstract

RNA interference (RNAi) has just made it through the pipeline to clinical trials. However, in order for RNAi to serve as an ideal personalized therapeutics and be clinically approved-safe, specific, and potent strategies must be devised for efficient delivery of RNAi payloads to specific cell types, which despite the immense potential, remains a challenge. Through evaluating the recent reported studies in this field, we introduce the progress in designing targeted nano-scaled strategies that are anticipated to overcome the delivery drawbacks and along with the exciting "omics" discipline to personalize RNAi-based therapeutics.

Original language	English
Pages (from-to)	1508-1521
Number of pages	14
Journal	Advanced Drug Delivery Reviews
Volume	64
Issue number	13
DOIs	https://doi.org/10.1016/j.addr.2012.08.014
State	Published - Oct 2012

Keywords

ApoB
BD
CME
CNT
Clinical trials
DC-6-14
DOPE
DOTAP
DOTMA
DsRNA
EPR
I.V.
In vivo
MAb
MPS
MW
MiRNA
NP
Nanoparticles
Nt
P.I.
PC
PEG
PEI
PK
Personalized medicine
RES
RISC
RNA
SNALP
ShRNA
Short interfering RNA (siRNA)
Systemic delivery
T
TLR

All Science Journal Classification (ASJC) codes

Pharmaceutical Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1016/j.addr.2012.08.014

Cite this

@article{5bdd817e81174cba903fbf5ec3e8f892,

title = "RNAi-based nanomedicines for targeted personalized therapy",

abstract = "RNA interference (RNAi) has just made it through the pipeline to clinical trials. However, in order for RNAi to serve as an ideal personalized therapeutics and be clinically approved-safe, specific, and potent strategies must be devised for efficient delivery of RNAi payloads to specific cell types, which despite the immense potential, remains a challenge. Through evaluating the recent reported studies in this field, we introduce the progress in designing targeted nano-scaled strategies that are anticipated to overcome the delivery drawbacks and along with the exciting {"}omics{"} discipline to personalize RNAi-based therapeutics.",

keywords = "ApoB, BD, CME, CNT, Clinical trials, DC-6-14, DOPE, DOTAP, DOTMA, DsRNA, EPR, I.V., In vivo, MAb, MPS, MW, MiRNA, NP, Nanoparticles, Nt, P.I., PC, PEG, PEI, PK, Personalized medicine, RES, RISC, RNA, SNALP, ShRNA, Short interfering RNA (siRNA), Systemic delivery, T, TLR",

author = "Ala Daka and Dan Peer",

note = "Funding Information: This work was supported in part by grants from the Marie Curie IRG-FP7 of the European Union, Lewis Family Trust, Israel Science Foundation (award no. 181/10 ), the Kenneth Rainin Foundation , the I-CORE Program of the Planning and Budgeting Committee and The Israel Science Foundation (grant no. 41/11 ) and the FTA: Nanomedicines for Personalized Theranostics of the Israeli National Nanotechnology Initiative to D.P.",

year = "2012",

month = oct,

doi = "https://doi.org/10.1016/j.addr.2012.08.014",

language = "الإنجليزيّة",

volume = "64",

pages = "1508--1521",

journal = "Advanced Drug Delivery Reviews",

issn = "0169-409X",

publisher = "Elsevier",

number = "13",

}

TY - JOUR

T1 - RNAi-based nanomedicines for targeted personalized therapy

AU - Daka, Ala

AU - Peer, Dan

N1 - Funding Information: This work was supported in part by grants from the Marie Curie IRG-FP7 of the European Union, Lewis Family Trust, Israel Science Foundation (award no. 181/10 ), the Kenneth Rainin Foundation , the I-CORE Program of the Planning and Budgeting Committee and The Israel Science Foundation (grant no. 41/11 ) and the FTA: Nanomedicines for Personalized Theranostics of the Israeli National Nanotechnology Initiative to D.P.

PY - 2012/10

Y1 - 2012/10

N2 - RNA interference (RNAi) has just made it through the pipeline to clinical trials. However, in order for RNAi to serve as an ideal personalized therapeutics and be clinically approved-safe, specific, and potent strategies must be devised for efficient delivery of RNAi payloads to specific cell types, which despite the immense potential, remains a challenge. Through evaluating the recent reported studies in this field, we introduce the progress in designing targeted nano-scaled strategies that are anticipated to overcome the delivery drawbacks and along with the exciting "omics" discipline to personalize RNAi-based therapeutics.

AB - RNA interference (RNAi) has just made it through the pipeline to clinical trials. However, in order for RNAi to serve as an ideal personalized therapeutics and be clinically approved-safe, specific, and potent strategies must be devised for efficient delivery of RNAi payloads to specific cell types, which despite the immense potential, remains a challenge. Through evaluating the recent reported studies in this field, we introduce the progress in designing targeted nano-scaled strategies that are anticipated to overcome the delivery drawbacks and along with the exciting "omics" discipline to personalize RNAi-based therapeutics.

KW - ApoB

KW - BD

KW - CME

KW - CNT

KW - Clinical trials

KW - DC-6-14

KW - DOPE

KW - DOTAP

KW - DOTMA

KW - DsRNA

KW - EPR

KW - I.V.

KW - In vivo

KW - MAb

KW - MPS

KW - MW

KW - MiRNA

KW - NP

KW - Nanoparticles

KW - Nt

KW - P.I.

KW - PC

KW - PEG

KW - PEI

KW - PK

KW - Personalized medicine

KW - RES

KW - RISC

KW - RNA

KW - SNALP

KW - ShRNA

KW - Short interfering RNA (siRNA)

KW - Systemic delivery

KW - T

KW - TLR

UR - http://www.scopus.com/inward/record.url?scp=84867642276&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.addr.2012.08.014

DO - https://doi.org/10.1016/j.addr.2012.08.014

M3 - مقالة مرجعية

SN - 0169-409X

VL - 64

SP - 1508

EP - 1521

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

IS - 13

ER -

RNAi-based nanomedicines for targeted personalized therapy

Abstract

Keywords

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this